SENTRY - A Synthetic Drug Early Warning and Response System
The National Drug Intelligence Center (NDIC) regrets to inform SENTRY users that the agency will no longer operate the SENTRY program as of November 1, 2011. However, NDIC will continue to produce and disseminate current intelligence reporting on new drugs and emerging trends to its customers, including former SENTRY users. Such reporting will be listed below. While SENTRY users can continue to provide input to NDIC via the SENTRY email address at NDIC.SENTRY@usdoj.gov, individuals are encouraged to provide information to NDIC via NDIC.Contacts@usdoj.gov.
Many federal agencies, including NDIC, are operating with decreased funding and making difficult decisions to balance agencies' missions with fiscal reality. NDIC appreciates the past participation of all SENTRY users and encourages them to continue providing drug-related information to NDIC.
